Pancreatic Cancer Research

ResearcherGeorgetown UniversityActive in the last 2 years

Aiwu Ruth He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2104-0816; OpenAlex author ID A5045096676. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: 2 papers

Papers 10

  1. Patterns of Failure Following Preoperative Chemotherapy and Stereotactic Body Radiation Therapy and Resection for Patients with Borderline Resectable or Locall… Co-author DOI 10.1007/s12029-023-00996-3↗
  2. Phase 1 Study of Hypofractionated Proton Beam Radiation Therapy in Adjuvant Pancreatic Cancer (PROTON-PANC). Co-author DOI 10.1016/j.ijrobp.2023.09.015↗
  3. A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy. Co-author DOI 10.1089/pancan.2020.0005↗
  4. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1301↗
  5. A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1089/pancan.2019.0003↗
  6. Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000118↗
  7. Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic c… Last author DOI 10.3892/ol.2016.4101↗
  8. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Last author DOI 10.1007/s00280-015-2855-z↗
  9. Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study. Co-author PMID 25276262↗
  10. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in… Co-author DOI 10.1002/cam4.137↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John Lindsay Marshall · 9 shared papers, 2014–2024 · strength 0.90
  2. Louis M. Weiner · 7 shared papers, 2015–2024 · strength 0.73
  3. Benjamin Adam Weinberg · 5 shared papers, 2014–2024 · strength 0.64
  4. Michael Jon Pishvaian · 7 shared papers, 2014–2020 · strength 0.53
  5. Keith Robert Unger · 3 shared papers, 2017–2024 · strength 0.43
  6. Emily R. Winslow · 2 shared papers, 2024 · strength 0.37
  7. Marcus Smith Noel · 2 shared papers, 2024 · strength 0.37
  8. Jimmy J. Hwang · 4 shared papers, 2014–2020 · strength 0.26
  9. Jonathan Robert Brody · 2 shared papers, 2019–2020 · strength 0.20
  10. Nicole Libbey · 1 shared paper, 2024 · strength 0.18
  11. Erik S. Knudsen · 1 shared paper, 2020 · strength 0.12
  12. Agnieszka Katarzyna Witkiewicz · 1 shared paper, 2020 · strength 0.12
  13. Brandon George Smaglo · 1 shared paper, 2020 · strength 0.11
  14. Zheng Wu · 2 shared papers, 2015–2016 · strength 0.10
  15. Marion L. Hartley · 1 shared paper, 2019 · strength 0.09
  16. Anteneh A. Tesfaye · 1 shared paper, 2019 · strength 0.09
  17. Marie Kate Gurka · 1 shared paper, 2017 · strength 0.06
  18. Xue‐Fei Tian · 1 shared paper, 2016 · strength 0.05
  19. Anton Wellstein · 1 shared paper, 2016 · strength 0.05
  20. Christina Sing-Ying Wu · 1 shared paper, 2014 · strength 0.04
  21. Selwyn Maurice Vickers · 1 shared paper, 2013 · strength 0.03
  22. Lucas Wong · 1 shared paper, 2013 · strength 0.03
  23. Andres Forero · 1 shared paper, 2013 · strength 0.03
  24. Mansoor Noorali Saleh · 1 shared paper, 2013 · strength 0.03
  25. Jeffrey R. Infante · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.